These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 11860837)
21. A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China. Li R; Huang L; Li J; Mo Z; He B; Wang Y; Wu X; Minutello M; Guinet-Morlot F; Pichon S Vaccine; 2013 Dec; 31(50):5940-7. PubMed ID: 24148575 [TBL] [Abstract][Full Text] [Related]
22. Comparative evaluation of immunogenicity, reactogenecity and safety of purified chick embryo cell rabies vaccine and neural tissue rabies vaccine. Deshpande AK; Londhe VA; Akarte S; Briggs D J Assoc Physicians India; 2003 Jul; 51():655-8. PubMed ID: 14621031 [TBL] [Abstract][Full Text] [Related]
24. [Comparison of PVRV and HDCV rabies vaccines as to immunity, reliability and protective value]. Hacibektaşoğlu A; Inal A; Eyigün C; Barut A; Türkay FA Mikrobiyol Bul; 1992 Jan; 26(1):26-36. PubMed ID: 1574019 [TBL] [Abstract][Full Text] [Related]
25. Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts. Tantawichien T; Jaijaroensup W; Khawplod P; Sitprija V Clin Infect Dis; 2001 Nov; 33(10):E122-4. PubMed ID: 11641838 [TBL] [Abstract][Full Text] [Related]
26. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group. Lang J; Simanjuntak GH; Soerjosembodo S; Koesharyono C Bull World Health Organ; 1998; 76(5):491-5. PubMed ID: 9868840 [TBL] [Abstract][Full Text] [Related]
27. BHK-21 cell culture rabies vaccine: immunogenicity of a candidate vaccine for humans. Lalosević D; Lalosević V; Lazarević-Ivanc Lj; Knezević I Dev Biol (Basel); 2008; 131():421-9. PubMed ID: 18634504 [TBL] [Abstract][Full Text] [Related]
28. [Comparative immunogenicity of 2 antirabies vaccines in a 2-1-1 post-exposure vaccination schedule]. Landry P; Lazzaro M; Darioli R Praxis (Bern 1994); 1998 Sep; 87(37):1177-9. PubMed ID: 9785997 [TBL] [Abstract][Full Text] [Related]
29. [Investigation of antibody levels following rabies vaccination in the subjects who were biten by animals]. Baysal B; Tosun S; Ozdemir M; Doğan M Mikrobiyol Bul; 2009 Jan; 43(1):127-31. PubMed ID: 19334389 [TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of purified chick embryo cell anti-rabies vaccine in post-exposure treatment of animal bite cases. Bhardwaj M; Bhattacharya D; Chhabra M; Ichhpujani RL J Commun Dis; 2002 Mar; 34(1):40-2. PubMed ID: 12718340 [TBL] [Abstract][Full Text] [Related]
31. [Biological characteristics of the adapted rabies virus 3aG-V in Vero cell]. Shi XS Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Dec; 18(4):348-50. PubMed ID: 15650786 [TBL] [Abstract][Full Text] [Related]
32. Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine. Malerczyk C; Briggs DJ; Dreesen DW; Banzhoff A J Travel Med; 2007; 14(1):63-4. PubMed ID: 17241256 [No Abstract] [Full Text] [Related]
33. Safety and immunogenicity of a new purified vero cell rabies vaccine (PVRV) administered by intramuscular and intradermal routes in healthy volunteers. Kulkarni PS; Sapru A; D'costa PM; Pandit A; Madhusudana SN; Yajaman AB; Mangrule S; Gunale B; Bavdekar AR Vaccine; 2013 May; 31(24):2719-22. PubMed ID: 23583817 [TBL] [Abstract][Full Text] [Related]
34. Production in Vero cells of an inactivated rabies vaccine from strain FRV/K for animal and human use. el-Karamany RM Acta Virol; 1987 Aug; 31(4):321-8. PubMed ID: 2892381 [TBL] [Abstract][Full Text] [Related]
35. Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine. Beran J; Honegr K; Banzhoff A; Malerczyk C Vaccine; 2005 Jun; 23(30):3902-7. PubMed ID: 15917111 [TBL] [Abstract][Full Text] [Related]
36. Development and evaluation of a competitive ELISA for estimation of rabies neutralizing antibodies after post-exposure rabies vaccination in humans. Muhamuda K; Madhusudana SN; Ravi V Int J Infect Dis; 2007 Sep; 11(5):441-5. PubMed ID: 17321182 [TBL] [Abstract][Full Text] [Related]
37. Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children. Vien NC; Feroldi E; Lang J Trans R Soc Trop Med Hyg; 2008 Mar; 102(3):294-6. PubMed ID: 18191971 [TBL] [Abstract][Full Text] [Related]
38. A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children. Sabchareon A; Lang J; Attanath P; Sirivichayakul C; Pengsaa K; Le Mener V; Chantavanich P; Prarinyanuphab V; Pojjaroen-Anant C; Nimnual S; Wood SC; Riffard P Clin Infect Dis; 1999 Jul; 29(1):141-9. PubMed ID: 10433577 [TBL] [Abstract][Full Text] [Related]
39. A comparative study on the immunogenicity, safety and tolerance of purified duck embryo vaccine (PDEV) manufactured in India (Vaxirab) and Switzerland (Lyssavac-N): a randomized simulated post-exposure study in healthy volunteers. Mahendra BJ; Madhusudana SN; Ashwathnarayana DH; Sampath G; datta SS; Sudarshan MK; Venkatesh GM; Muhamuda K; Bilagumba G; Shamanna M Vaccine; 2007 Dec; 25(50):8405-9. PubMed ID: 17981377 [TBL] [Abstract][Full Text] [Related]
40. [An epidemiological study of rabies virus in domestic dogs, cats and wildlife and the immunogenicity study for rabies vaccines derived from different cell cultured virus strains]. Dong GM; Xu GL; Xiao QY; Wang DM; Hu YM; Zhou DJ; Wang P; Zhang YZ; Yang XM; Zhu FC; Wang ZX; Luo SB; Luo TY Bing Du Xue Bao; 2007 Nov; 23(6):417-23. PubMed ID: 18092676 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]